Renaissance Technologies
ANTX icon

Renaissance Technologies’s AN2 Therapeutics ANTX Stock Holding History

Renaissance Technologies’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$628K Sell
129,700
-69,100
-35% -$297K ﹤0.01% 2514
2026
Q1 		$680K Sell
198,800
-139,800
-41% -$289K ﹤0.01% 2462
2025
Q4 		$386K Sell
338,600
-46,997
-12% -$54.9K ﹤0.01% 2678
2025
Q3 		$490K Sell
385,597
-13,257
-3% -$15.2K ﹤0.01% 2805
2025
Q2 		$423K Buy
398,854
+30,146
+8% +$35.9K ﹤0.01% 2922
2025
Q1 		$501K Sell
368,708
-211,065
-36% -$266K ﹤0.01% 2742
2024
Q4 		$800K Buy
579,773
+155,973
+37% +$189K ﹤0.01% 2608
2024
Q3 		$453K Buy
423,800
+409,500
+2,864% +$711K ﹤0.01% 2833
2024
Q2 		$30.7K Buy
+14,300
New +$34K ﹤0.01% 3338
2022
Q4 		– Sell
-22,000
Closed -$382K – 4094
2022
Q3 		$382K Sell
22,000
-3,700
-14% -$43.1K ﹤0.01% 3076
2022
Q2 		$199K Buy
+25,700
New +$340K ﹤0.01% 3651

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return

Renaissance Technologies's ANTX Position: Q2 2026 in Review

Renaissance Technologies reduced its AN2 Therapeutics (ANTX) stake by 35% in Q2 2026, selling an estimated $297K and leaving 129,700 shares worth $628K. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

Renaissance Technologies first reported a position in ANTX in Q2 2022 and has held it in 11 quarters since. The position peaked at $800K in Q4 2024. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Renaissance Technologies held 129,700 shares of AN2 Therapeutics worth $628K as of Q2 2026.
  • Renaissance Technologies sold 69,100 AN2 Therapeutics shares in Q2 2026, an estimated $297K.
  • AN2 Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2514 holding.
  • Renaissance Technologies first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Renaissance Technologies's AN2 Therapeutics position peaked at $800K in Q4 2024.
  • 59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.